{"organizations": ["Synthetic Biologics"], "uuid": "8a9e9463552e4ffdbaa35a4bf75eaf45e70956ff", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://feeds.bio-medicine.org/latest-biology-technology", "section_title": "Latest Biology Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/biology-technology-1/Synthetic-Biologics-to-Report-Third-Quarter-Results-on-November-5--2015-34390-1/", "country": "US", "title": "Synthetic Biologics to Report Third Quarter Results on November 5, 2015", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Synthetic Biologics to Report Third Quarter Results on November 5, 2015", "spam_score": 0.0, "site_type": "news", "published": "2015-10-19T14:30:00.000+03:00", "replies_count": 0, "uuid": "8a9e9463552e4ffdbaa35a4bf75eaf45e70956ff"}, "author": "", "url": "http://www.bio-medicine.org/biology-technology-1/Synthetic-Biologics-to-Report-Third-Quarter-Results-on-November-5--2015-34390-1/", "ord_in_thread": 0, "title": "Synthetic Biologics to Report Third Quarter Results on November 5, 2015", "locations": ["U.S."], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Synthetic Biologics to Report Third Quarter Results on November 5, 2015 ... ROCKVILLE Md. Oct. 19 2015 /...U.S. (toll free): 1-888-347-5280 International: +1 412-902-4280 !-- Paragraph before: Synthetic B... http://feeds.bio-medicine.org/latest-biology-technology Date:10/19/2015 \nROCKVILLE, Md. , Oct. 19, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September 30, 2015 on Thursday, November 5, 2015, and to host a conference call the same day at 4:30 p.m. EST. The dial-in information for the call is as follows: \nU.S. (toll free): 1-888-347-5280International: +1 412-902-4280 \nParticipants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/11196 . An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/11196 , beginning approximately one hour after the call's conclusion. \nAbout Synthetic Biologics, Inc. \nSynthetic Biologics, Inc. (NYSE MKT: SYN) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon Corporation (NYSE: XON ), a monoclonal antibody combination for the treatment of Pertussis and biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com .", "external_links": [], "published": "2015-10-19T14:30:00.000+03:00", "crawled": "2015-10-19T16:21:37.223+03:00", "highlightTitle": ""}